Advertisement

Presentation and Evaluation of Immune Thrombocytopenia

  • Vicky R. Breakey
Chapter

Abstract

Immune thrombocytopenia (ITP) often presents clinically as petechiae, bruising, and/or mucocutaneous bleeding with an acute onset. Severe bleeding at the time of presentation is rare but can be life threatening. A detailed clinical history, including a review of the patient’s family history, is important to assess for possible inherited and/or secondary causes of thrombocytopenia (see Chap.  1). The physical examination reveals an otherwise healthy individual with skin bruising, purpura, and/or petechial rash in the absence of other findings, specifically lymphadenopathy or hepatosplenomegaly, or other systemic signs/symptoms such as fever, fatigue, weight loss, malaise, and/or pain. The diagnosis of primary ITP is one of exclusion and relies on ruling out other causes of thrombocytopenia in addition to a careful review for conditions associated with secondary ITP. The initial investigations often show severe thrombocytopenia, with variable to high mean platelet volume (MPV). In otherwise typical presentations, no additional testing is needed. The role of bone marrow testing remains controversial and is generally reserved for patients with an uncertain diagnosis or an atypical course.

Keywords

Thrombocytopenia Bleeding diathesis Autoimmune disorders 

References

  1. 1.
    Kuhne T, Imbach P, Bolton-Maggs PH, Berchtold W, Blanchette V, Buchanan GR, et al. Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study. Lancet. 2001;358(9299):2122–5.CrossRefPubMedGoogle Scholar
  2. 2.
    Kenet G, Lubetsky A, Shenkman B, Tamarin I, Dardik R, Rechavi G, et al. Cone and platelet analyser (CPA): a new test for the prediction of bleeding among thrombocytopenic patients. Br J Haematol. 1998;101(2):255–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Page LK, Psaila B, Provan D, Hamilton JM, Jenkins JM, Elish AS, et al. The immune thrombocytopenic purpura (ITP) bleeding score: assessment of bleeding in patients with ITP. Br J Haematol. 2007;138(2):245–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Khellaf M, Michel M, Schaeffer A, Bierling P, Godeau B. Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count. Haematol-Hematol J. 2005;90(6):829–32.Google Scholar
  5. 5.
    Pansy J, Minkov M, Dengg R, Quehenberger F, Lackner H, Nebl A, et al. Evaluating bleeding severity in children with newly diagnosed immune thrombocytopenia: a pilot study. Klin Padiatr. 2010;222(6):374–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Neunert C, Noroozi N, Norman G, Buchanan GR, Goy J, Nazi I, et al. Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review. J Thromb Haemost. 2015;13(3):457–64.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Patel AP. Idiopathic autoimmune thrombocytopenia and neutropenia in siblings. Eur J Haematol. 2002;69(2):120–1.CrossRefPubMedGoogle Scholar
  8. 8.
    Rischewski JR, Imbach P, Paulussen M, Kühne T. Idiopathic thrombocytopenic purpura (ITP): is there a genetic predisposition? Pediatr Blood Cancer. 2006;47(S5):678–80.CrossRefPubMedGoogle Scholar
  9. 9.
    Drachman JG. Inherited thrombocytopenia: when a low platelet count does not mean ITP. Blood. 2004;103(2):390–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Arnold DM, Kukaswadia S, Nazi I, Esmail A, Dewar L, Smith JW, et al. A systematic evaluation of laboratory testing for drug-induced immune thrombocytopenia. J Thromb Haemost. 2013;11(1):169–76.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Mantadakis E, Farmaki E, Buchanan GR. Thrombocytopenic purpura after measles-mumps-rubella vaccination: a systematic review of the literature and guidance for management. J Pediatr. 2010;156(4):623–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Serrando M, Marull A, Ruiz M, Perez Del Campo D, Puig-Pey I, Munoz JM, et al. Clinical significance of IPF% measurement in diagnosing thrombocytopenic disorders: distinguishing primary immune thrombocytopenia from other disorders. Int J Lab Hematol. 2016;38(3):e65–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168–86.CrossRefPubMedGoogle Scholar
  14. 14.
    Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190–207.CrossRefPubMedGoogle Scholar
  15. 15.
    Evans RS, Takahashi K, Duane RT, Payne R, Liu C. Primary thrombocytopenic purpura and acquired hemolytic anemia; evidence for a common etiology. AMA Arch Intern Med. 1951;87(1):48–65.CrossRefPubMedGoogle Scholar
  16. 16.
    Aledort LM, Hayward CP, Chen MG, Nichol JL, Bussel J, Group ITPS. Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. Am J Hematol. 2004;76(3):205–13.CrossRefPubMedGoogle Scholar
  17. 17.
    Altintas A, Ozel A, Okur N, Okur N, Cil T, Pasa S, et al. Prevalence and clinical significance of elevated antinuclear antibody test in children and adult patients with idiopathic thrombocytopenic purpura. J Thromb Thrombolysis. 2007;24(2):163–8.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of PediatricsMcMaster UniversityHamiltonCanada

Personalised recommendations